Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Sponsor: China National Center for Cardiovascular Diseases
Summary
In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.
Official title: Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-01-19
Completion Date
2026-12-31
Last Updated
2026-03-05
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 MG
Each participant in the empagliflozin treatment group takes a daily dose of 10mg.
Placebo
Each participant in the placebo group takes matching placebo.
Locations (2)
Fuwai Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen
Shenzhen, Guangdong, China